Gland Pharma surges on receiving USFDA`s approval for Acetaminophen Injection
Gland Pharma is currently trading at Rs. 1592.50, up by 57.40 points or 3.74% from its previous closing of Rs. 1535.10 on the BSE.
The scrip opened at Rs. 1742.45 and has touched a high and low of Rs. 1755.00 and Rs. 1581.85 respectively. So far 66829 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2220.95 on 06-Aug-2024 and a 52 week low of Rs. 1412.00 on 12-Feb-2025.
Last one week high and low of the scrip stood at Rs. 1755.00 and Rs. 1527.10 respectively. The current market cap of the company is Rs. 26319.84 crore.
The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 39.84% and 8.33% respectively.
Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for Acetaminophen Injection, 10 mg/mL (500mg/50mL and 1000mg/100mL) Bags. The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Acetaminophen Injection, 500 mg/50 mL (10 mg/mL) and 1000 mg/100 mL (10 mg/mL), of B. Braun Medical, Inc.
This product is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older, as well as moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients 2 years and older. The company expects to launch this product through its marketing partner in the near future. According to IQVIA, the product had US sales of around $55 million for the twelve months ending February 2025.
Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.
